Warhound Emerges with $200M to Genetically Engineer Enhanced War Dogs for Military and Law Enforcement

Image: TechCrunch · Source

Warhound, founded by Ben Lamm and Palmer Luckey, secured $200 million to create genetically enhanced working dogs equipped with Anduril technology for U.S. military and law enforcement.

Warhound, a new venture co-founded by Colossal Biosciences’ Ben Lamm and Anduril co-founder Palmer Luckey, has publicly launched with $200 million in funding from major investors including In-Q-Tel, Sequoia Capital, and 8VC. Valued at $1.2 billion, Warhound aims to address critical shortages in high-quality military and law enforcement working dogs by genetically engineering canines with superior traits suited for demanding operational roles.

Currently, over 80% of U.S. military working dogs are sourced from Europe, with fewer than half deemed fit for service. This reliance on foreign-bred dogs poses supply challenges and potential risks. Warhound plans to use Colossal’s pioneering gene editing technologies to enhance desirable characteristics such as health, longevity, speed, agility, and olfactory sensitivity for tasks like bomb detection and search operations.

Ben Lamm explained that after meeting Luckey about a year prior and researching challenges in dog breeding for service roles—including genetic predispositions to health issues like cancer, hip dysplasia, and muscle atrophy—the team selected top-performing breeds like Belgian Malinois and German Shepherds. They banked cell lines from these breeds and plan to edit genes to amplify performance traits while removing undesirable ones, effectively creating a new category of genetically enhanced working dogs.

In parallel, Anduril will contribute advanced hardware and software enhancements, including protective bulletproof vests equipped with data sensors and situational awareness tools such as eye goggles. These innovations aim to increase the safety and coordination effectiveness of both dogs and their handlers in the field.

Warhound’s first genetically edited dogs are nearing cloning and incubation, with births expected in early 2027 and entry into active service within two years. The cloning process is supported by Viagen, another Colossal-owned company with a high cloning success rate currently used for endangered species programs.

Although pricing has not been finalized, Warhound anticipates customers will include the U.S. Department of Defense, military service groups, police forces, and first responders. The company has engaged extensively with government agencies and adheres to ethical standards, working alongside the American Humane Society to certify training protocols. Retired dogs are expected to be integrated into existing humane care programs such as the Military Working Dog Reunification Program.

Palmer Luckey is involved as a partner but does not hold equity; Colossal Biosciences owns equity and licenses its technology to Warhound. This initiative is one of the first to combine cutting-edge genetic engineering with tactical enhancements to address operational and welfare challenges in military service dogs, potentially transforming their role and effectiveness in national security and public safety missions.